Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.
Dating back to ancient Egypt, immunotherapy has a rich history of harnessing the power of the immune response to treat diseases. Today, immunotherapy is routinely used to fight cancer and treat viral diseases.
Abstract In this on-demand webinar, we briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies. Webinar details [...]
Abstract In this on-demand webinar, we discuss why it is important to characterize antibodies based on their physical properties not just by what they bind, and how you can easily do the former via mass spectrometry-based protein sequencing. Key Takeaways Antibodies are generally characterized based on what they bind, not their [...]
Overcoming Irreproducibility in Life Science Research Sponsored by: Rapid Novor, Inc & Absolute Antibody Our team, along with four other industry panelists, discuss ways to safeguard their research through recombinant antibodies, cell culturing procedures, antibody protein sequences, and reference identifiers. Full Webinar Panelists: Andrew Bradbury, CSO at Specifica “Drug-Like Antibodies from [...]
The protein sequence is key to understanding the function of a protein target, and is critical to therapeutic and diagnostic development. This is particularly important for antibodies whose code diversity and glycosylation impact both function, and stability.
Antibody sequences are critical for antibody engineering and protein characterization in therapeutic development. For antibody reagent users, knowing the sequences allows them to perform sequence analysis/alignment to identify binding and cross-reactivity so they can conduct rational experiment design.
Amino acid sequencing is the process of identifying the arrangement of amino acids in proteins and peptides. Numerous distinct amino acids have been discovered in nature but all proteins in the human body are comprised of just twenty different types.
Monoclonal antibodies (mAbs) are widely used in research, diagnosis, and pharmaceutical purposes. Lately, the relatively lower quality of research-purpose mAbs is a point of concern within the research community.
In this study, we conducted a large-scale statistical analysis of protein sequencing data from samples digested with multiple proteases to understand the impact of using different combinations of proteases to improve the depth of sequence coverage in the application of de novo protein sequencing.
Written by María Gerpe, PhD June 18, 2021 Introduction Research publications represent an additional source of validation proof for commercially available antibodies. As such, academic and industry scientists often also rely on publication references to decide which commercial antibody to purchase. Several independent efforts exist to compile such information. For instance, [...]
A Large-Scale Comparison of MS-based Antibody De Novo Protein Sequencing and Targeted DNA Sequencing
The DNA sequences of antibodies are highly diverse due to the V-(D)-J recombination and hypersomatic mutations. As such, relying on homology-based searches to sequence novel antibodies can introduce bias to sequences obtained from proteomics approaches.
Antibodies are integral to life sciences research and therapeutic and diagnostics discovery and development. However, they are inherently prone to variability.
Mouse monoclonal antibodies (mAbs) are highly attractive for manipulation for therapeutic applications as their manufacturing is relatively easy and well-established compared to mAbs derived from larger animal models. However, they also pose several challenges which limits their use as therapeutic agents.
In vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions, and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.
We are able to sequence any species because we use de novo protein sequencing by tandem mass spectrometry (MS/MS). This type of protein sequencing by mass spectrometry does not rely on existing databases that might introduce bias or wrong amino acid calls.
We recommend that you ship your samples either lyophilized or in solution. If your samples are already lyophilized it is best to ship them to us in that form, they can be shipped at ambient temperatures, and are suitable for transfers longer than 24h.
How much protein and what purity is needed for protein sequencing? A: We typically accept samples at 100 µg with at least 80% purity, rare in the field. To measure the amount of protein, you can use a microvolume spectrophotometer such as the Nanodrop or a traditional Bradford assay.
The most common protein contaminants include keratin and serum albumin. Other Mass Spectrometry (MS) protein contaminants identified in research labs worldwide by a recent Human Proteome Organization study are casein and E. coli proteins.
Nowadays, DNA sequencing is so popular that it is easy to forget that the first sequenced biological material was protein – insulin, by Sanger. Sanger, and another researcher, Edman, separately pioneered protein sequencing.
In-Depth Characterization of Monoclonal Antibodies with a Single Experiment and Fully Automated Data Analysis
This is a hand crafted super awesome extract that is inserted into the "Excerpt" field below the post editing area. These excerpts will be used instead of pulling the first lines of text from the article body and can resolve issues where the first lines are author bylines, etc.
Recombinant Monoclonal Antibodies (rAbs) are highly reproducible, customizable and pure alternatives to the traditional antibodies produced by hybridomas. Get the antibody protein sequence, either by DNA sequencing or the de novo protein sequencing technology, you can rest assured that you can have the exact antibody made recombinantly anytime in the future.